Should You Wean Off Mounjaro Before Stopping?

Does Mounjaro need to be tapered, or can you stop it outright?

The Mounjaro Summary of Product Characteristics does not include a mandatory tapering schedule. This distinguishes tirzepatide from certain antidepressants or corticosteroids, where step-down is a clinical necessity to avoid withdrawal effects. Stopping Mounjaro does not trigger a classic pharmacological withdrawal, there are no documented rebound hormonal surges or dependency patterns of that kind.

What does happen is more straightforward. The appetite suppression tirzepatide produces fades as the drug clears your system, typically over the course of the weeks following your last dose. Hunger returns, gastric emptying speeds back up, and the physiological signals that made eating less feel natural begin to normalise. For some people that shift is gradual; for others it feels quite sudden.

Whether that means you should step down rather than stop outright is a different question, and the honest answer is that good-quality evidence specifically on tapering strategies for tirzepatide is thin. Some prescribers advocate a step-down through lower doses as a practical buffer; others consider an abrupt stop appropriate depending on the dose and the patient's circumstances. The right call depends on your current dose, how long you have been on treatment, and what your plan is for maintaining progress afterwards. A conversation with your prescriber (not a general article) is where that decision belongs. If you are currently under clinical supervision and want to explore your options, guidance on whether Mounjaro is right for your situation may help frame that discussion.

What actually happens to your weight when you stop Mounjaro?

This is perhaps the most important question behind the weaning question, and the data here are clear enough to be useful. The SURMOUNT-1 extension analysis and similar post-treatment follow-up data show that without continued treatment or sustained lifestyle change, a significant portion of weight lost on tirzepatide returns, often the majority of it, within around a year. This is not a failure of willpower; it reflects the biology of weight regulation. Mounjaro works in part by suppressing appetite signals through GIP and GLP-1 receptor activity. Remove that suppression and the body's homeostatic drives reassert themselves.

That finding matters for the weaning question because it shifts the frame. If you are considering stopping, the bigger clinical conversation is usually about what replaces it (a structured diet and activity programme, follow-up monitoring, or a planned return to treatment at a later stage) rather than the exact shape of the final few weeks on the pen. You can read more about practical approaches to coming off Mounjaro on a dedicated page.

There is also a related question worth sitting with: are you stopping because you have reached your goal and feel ready, because of a side effect, or because of cost or access? Each of those has a different clinical answer. A quick check worth doing before stopping is to log your current weight and compare it with where you started, a one-minute task that gives your prescriber useful context.

Are there any risks to stopping Mounjaro suddenly?

For most people at lower doses (2.5mg or 5mg), stopping suddenly carries modest practical risk, mainly the return of appetite and the psychological adjustment that comes with it. At higher doses (10mg, 12.5mg or 15mg), some people report that the contrast between appetite-suppressed and appetite-restored feels more marked, which is one clinical rationale for stepping down rather than stopping sharply.

Gastrointestinal symptoms are worth considering too. Some people experience a settling-in period when they reduce or stop tirzepatide, not identical to the nausea some feel when starting, but a system adjusting again. This is usually mild and short-lived. Serious adverse effects from simply stopping the medicine, rather than from the medicine itself, are not a recognised pattern in the clinical data.

Where risk is more specific is in people using tirzepatide to manage type 2 diabetes alongside weight, or those with cardiovascular conditions where weight management forms part of a broader clinical plan. Stopping in those contexts without a medical review carries more consequence. The NICE appraisal of tirzepatide (TA1026) is informative on the clinical context, and your GP should be informed of any change to your treatment. There is more on weighing up the decision overall at whether weaning off Mounjaro is necessary for you.

What should the conversation with your prescriber cover?

If you are thinking about stopping Mounjaro, your prescriber will typically want to know a few things: how long you have been on treatment, your current dose, how much weight you have lost and how stable that has been, your reasons for considering stopping, and what your plan is for the months that follow. These shape whether a taper makes sense, how it might look, and whether a pause rather than a stop might be worth considering.

It is also worth knowing that under UK clinical guidance, prescribers are expected to review progress at six months on the maintenance dose, if less than 5% weight loss has been achieved, continuing is reassessed. That review is also a natural moment to have the stopping conversation, rather than making the decision between appointments.

If you are weighing up treatment more broadly, the question of whether starting Mounjaro is right for you covers eligibility and what the clinical assessment involves. For those thinking about cost alongside the stopping question, context on Mounjaro pricing in the UK may be relevant, affordability is a legitimate reason to plan a stop, and a prescriber can help think through that honestly. At our Mounjaro overview you will find a fuller picture of the treatment, and our clinical team reviews every patient case personally. If you would like to discuss your own situation with a prescriber, you are welcome to start a free consultation at any point.